Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European marketORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST
- Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Hims & Hers (HIMS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/1/2026
- The Rosen Law Firm PAROSEN, A LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockSpyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company's common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.
- NetflixNetflix Unveils Date and First-Look Images for Medical Drama ‘Always on Call’Companies: Netflix, Inc.Netflix Unveils Date and First-Look Images for Medical Drama ‘Always on Call’
- Kessler Topaz Meltzer & Check, LLPHIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the FirmDid you buy HIMS securities between August 4, 2025 and July 29, 2026? Affected HIMS Investor Summary Who: Hims & Hers Health, Inc. (NYSE: HIMS) What: Securities fraud class action lawsuit filed Class Period: August 4, 2025 through July 29, 2026 Deadline to Seek Lead Plaintiff Status:...
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 59,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,550 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
- Mozart TherapeuticsMozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual MeetingPresentations highlight Phase 1 clinical findings, proof-of-mechanism data, and translational evidence supporting the therapeutic potential of MTX-101 in adults and adolescents with Stage 3 type 1 diabetes SEATTLE, Oct. 5, 2026 -- Mozart Therapeutics, Inc. ("Mozart"), the...
- Decent Holding Inc. Announces Closing of $1.23 Million Follow-on OfferingDecent Holding Inc. (NASDAQ: DXST) (the “Company”), a technology-driven provider of wastewater treatment and community-based senior health and elderly care services in China, today announced the closing of its previously announced follow-on offering to an institutional investor for the sale of (i) in a registered direct offering, 822,828 Class A ordinary shares, par value of $0.0025 per share, of the Company (the “Class A Ordinary Shares”) or, in lieu thereof, pre-funded warrants, at a purchase price of $1.50 per share; and (ii) in a concurrent private placement, unregistered warrants (the “Unregistered Warrants”) to purchase up to 822,828 Class A Ordinary Shares, with an exercise price of $1.50 per share (together, the “Securities”). The offering closed on October 05, 2026.
- Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesVaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to grant the underwriters a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments. The completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when either offering may be completed, or as to the actual size or terms of either offering.
- agilon health Sets Date to Report Third Quarter 2026 Financial ResultsWESTERVILLE, Ohio, October 05, 2026--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026 and host a conference call at 4:30 p.m. ET to discuss the results.